Tech Company Financing Transactions
Curemark Funding Round
Private investors invested in a $5 million funding round for Curemark. This venture round was announced on 1/14/2015.
Transaction Overview
Company Name
Announced On
1/14/2015
Transaction Type
Debt
Amount
$5,000,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed. SEC regulatory filing - amended. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
411 Theodore Fremd Ave. 206
Rye, NY 10580
USA
Rye, NY 10580
USA
Phone
Website
Email Address
Overview
Curemark is a socially driven biotechnology company focused on the treatment of Autism and other neurological diseases. The company is committed to improving the quality of life for children and adults with neurological disorders by providing safe, effective and clinically proven solutions.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Joan Fallon
Chief Medical Officer
William Gannon
Chief Operating Officer
Jzaneen Lalani
VP - R & D
Matthew Heil
Browse more venture capital transactions:
Prev: 1/14/2015: Proclara Biosciences venture capital transaction
Next: 1/14/2015: Elsen venture capital transaction
Share this article
About Database of VC Transactions
We do our best to report on tech company VC transactions. All VC database entries on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs